
zzso zzso is a major adverse event associated with most of the zzso zzso chemotherapy zzso zzso a zzso analogue of the natural zzso B, has activity against a wide range of tumor zzso zzso zzso zzso associated with zzso treatment, is usually mild to moderate, predominantly sensory and zzso zzso studies demonstrate that zzso and zzso produce a similar zzso zzso 

We searched databases of phase zzso clinical trials involving patients receiving zzso as a zzso or in combination with zzso for zzso of zzso Potential risk factors for grade 3/4 zzso were identified by a Cox zzso analysis on a zzso of zzso patients with different tumor types across multiple zzso 

Rates for zzso of zzso severe zzso zzso zzso zzso for zzso Events grade zzso ranged from zzso in early zzso breast cancer up to zzso in heavily zzso zzso breast zzso grade 4 zzso was rare zzso zzso Common symptoms included zzso zzso and sometimes zzso Cox zzso analysis identified only zzso zzso as a risk factor for increased zzso zzso The management of zzso has been primarily through dose adjustments zzso delays and/or dose zzso Patients had resolution of their zzso within a median time of 5 to 6 zzso 

zzso is a zzso toxicity associated with zzso treatment, is zzso in most patients, and can be managed with dose reduction and zzso 

